Studies of the immune response in heparin-induced thrombocytopenia

Blood

Volumn 113, Issue 20, 2009, Pages 4963-4969

  Warkentin, Theodore E ^a   Sheppard, Jo Ann I ^a   Moore, Jane C ^a   Cook, Richard J ^b   Kelton, John G ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEPARIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; THROMBOCYTE FACTOR 4 ANTIBODY; UNCLASSIFIED DRUG; THROMBOCYTE FACTOR 4;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; PLASMA; PRIORITY JOURNAL; SEROCONVERSION; SEROLOGY; THROMBOCYTE COUNT; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENE REARRANGEMENT; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TIME;

ANTIBODIES; CASE-CONTROL STUDIES; HEPARIN; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN M; PLATELET COUNT; PLATELET FACTOR 4; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTOPENIA; TIME FACTORS;

EID: 65349122236     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-186064     Document Type: Article

References (27)

1. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809-817.
2. Warkentin TE. Drug-induced thrombocytopenia - from purpura to thrombosis. N Engl J Med. 2007;356:891-893.
3. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2001;113:886-890. (Pubitemid 32634754)
4. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007;5:1666-1673. (Pubitemid 47091409)
5. Warkentin TE, Sheppard JI, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med. 2005;146:341-346.
6. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95-96.
7. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparinin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182-187.
8. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1998;72:925-930.
9. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Platelet P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83:1535-1541. (Pubitemid 24081566)
10. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-11399
11. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
12. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
13. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest. 2002;122:37-42. (Pubitemid 34754140)
14. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357:1903-1915.
15. Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [letter]. N Engl J Med. 2000;343:515. (Pubitemid 30646499)
16. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl):340S-380S. (Pubitemid 351892970)
17. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114:545-1511
18. Warkentin TE, Ling E, Ho A, Sheppard JI. 'Incidental' unfractionated heparin (UFH) vs normal saline (NS) flushes for intraoperative invasive catheters and the frequency of formation of heparin-induced thrombocytopenia of IgG antibodies (HIT-IgG): a randomized, controlled trial [abstract]. Blood. 1998;92(suppl 1):91b.
19. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708. (Pubitemid 30661052)
20. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518-2524. (Pubitemid 37385796)
21. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:371-379.
22. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.
23. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138:22-31. (Pubitemid 32589199)
24. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95:161-167.
25. Lee JJ, Hess KR, Dubin JA. Extensions and applications of event charts. Am Stat. 2000;54:63-70.
26. The production of effectors. In: Delves PJ, Martin SJ, Burton DR, Roitt IM, eds. Roitt's Essential Immunology. 11th Ed. Malden, MA: Blackwell Publishing Ltd; 2006:185-210.
27. Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood. 2007;110:1153-1160. (Pubitemid 47281411)